Intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to morning glory syndrome in a child

Congenital optic nerve abnormalities may rarely cause choroidal neovascularization [CNV]. This case report summarizes the clinical and therapeutic outcomes of a 7-year-old boy with unilateral CNV secondary to morning glory syndrome associated with acute visual acuity loss. The patient was successfully treated with a single intravitreal ranibizumab injection. One month after the injection the visual acuity increased and optic coherence tomography [OCT] showed a decrease in the intraretinal fluid around the CNV. The patient was then called for monthly follow-up visits. No further treatment was needed for the next 12 months after the first treatment. There was no complication related to the injection

case of nodular posterior scleritis mimicking choroidal mass

The aim of this study is to report clinical and imaging findings, and treatment outcomes of a patient with nodular posterior scleritis. A 41-year-old woman was diagnosed as nodular posterior scleritis in the light of clinical and imaging findings. At first admission best corrected visual acuity was 20/50 in her right eye. Fundus examination revealed an amelanotic subretinal mass under the superior temporal arcade associated with subretinal fluid surrounding it. B-scan ultrasonography, optical coherence tomography, fluorescein angiography, and indocyanine green angiography findings confirmed the diagnosis. As treatment, nepafenac eye drops 3 times a day, and flurbiprofen tablet 100 mg twice a day were prescribed. After 4 weeks of treatment, the ocular pain was relieved, BCVA improved to 20/20, and subretinal mass totally regressed. Although the diagnosis of nodular posterior scleritis may be confusing, it has to be kept in mind in patients with a subretinal/choroidal mass. Multimodal fundus imaging may be helpful in differential diagnosis. The condition is usually curable with non-steroidal anti-inflammatory drugs and/or systemic steroids

Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a report of two patients

The aim of this study is to report clinical course of choroidal neovascularization secondary to angioid streaks [AS] in two patients who underwent intravitreal bevacizumab therapy. Fundus examination, fluorescein angiography [FA] and optical coherence tomography [OCT] revealed the diagnosis of subfoveal classic choroidal neovascularization [CNV] in the right eye in patient 1 and in the left eye in patient 2. After three consecutive bevacizumab injections, visual acuity improved from 20/40 to 20/25 in patient 1 and from 20/80 to 20/50 in patient 2. After 3 months of therapy, additional bevacizumab injection was administered when the lesion showed recurrence. After a follow-up time of 24-months, patient 1 received 14 intravitreal bevacizumab injections; patient 2 received only 4 injections. Visual acuities remained stable at 20/32 and 20/50 in patient 1 and patient 2, respectively. Though, the patients of CNV secondary to AS showed similar clinical appearance at the beginning, this report provides the data for different responses to intravitreal bevacizumab therapy. While fewer injections were required to control the disease in one patient, the other patient needed much more injections for stabilization of the CNV. Further studies are required to understand the cause of varied treatment responses in those patients

Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2

The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the proliferative stage. In the proliferative period, the patient was treated with intravitreal bevacizumab injections as-clinically warranted. Over a follow up period lasting 26 months, the patient received 6 intravitreal bevacizumab injections, the visual acuity improved from 20/100 to 20/40, the central retinal thickness decreased from 318 microns to 198 microns. This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2

Long-term results of phacoemulsification combined with primary posterior curvilinear capsulorhexis in adults

To evaluate the 2-year outcomes of phacoemulsification combined with primary posterior curvilinear capsulorhexis [PPCC] in adults. In this retrospective case series, 93 eyes of 91 patients with bilateral age-related cataract who underwent phacoemulsification combined with PPCC were evaluated. The study included cases due to postoperative residual posterior capsule opacification despite careful polishing. Data were evaluated on preoperative and postoperative best corrected visual acuity [CDVA] [Snellen acuity], slit-lamp biomicroscopy and intraocular pressure [IOP] measurement. Perioperative and postoperative complications were also recorded. The mean follow-up was 24.9 +/- 13.5 months [range, 12-53 months]. At the last visit, 87.1% of the eyes had CDVA>/=20/40 and 58% had>/=20/25. Posterior capsular opacification [PCO] occurred in 2 [2.2%] of patients. No serious complications such as retinal detachment and endophthalmitis were observed during follow-up. Cataract surgery combined with PPCC is a safe procedure with a low rate of complications over the long term. This procedure reduced the necessity of Nd:YAG laser capsulotomy in adults with postoperative residual posterior capsule opacification despite careful polishing

Combined 23-gauge transconjunctival sutureless vitrectomy and cataract surgery in cases with cataract and posterior segment diseases

Combined cataract surgery and transconjunctival sutureless vitrectomy are a good option in patients with cataract and vitreoretinal diseases. To evaluate the effectiveness, outcomes, and complications of combined 23-gauge transconjunctival sutureless vitrectomy and cataract surgery. A retrospective case series was conducted at the Beyoglu Eye Education and Research Hospital. In this study, 28 eyes of 28 patients underwent combined 23-gauge transconjunctival sutureless vitrectomy and phacoemulsification and IOL implantation for cataract and various posterior segment diseases. The outcome measures included, visual acuity, intraocular pressure changes, and anatomical success were evaluated. The mean follow-up was 4.8 months [range, 3-15 months]. Mean overall preoperative visual acuity was 20/333, and final acuity was 20/95 [P < 0.001]. Mean intraocular pressure [IOP] on the preoperative and first postoperative day was 15.6 +/- 7.5 and 13.8 +/- 3.3 mmHg, respectively [P > 0.05]. Three eyes [10.7%] had postoperative hypotony [<6 mmHg]that all recovered spontaneously within the first postoperative week. Three eyes [10.7%] required laser treatment for iatrogenic retinal tears. Anatomical success was obtained in all cases. No serious complications such as endophthalmitis were observed during the follow-up period. Combined transconjunctival sutureless vitrectomy and phacoemulsification was effective and safe in patients with significant lens opacities and vitreoretinal pathology. Although the anatomic and visual outcomes were satisfactory, the outcomes depended mainly on underlying vitreoretinal pathology